Compare LITM & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITM | ACRV |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 64.7M |
| IPO Year | 2021 | 2022 |
| Metric | LITM | ACRV |
|---|---|---|
| Price | $3.83 | $1.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 433.5K | ★ 3.6M |
| Earning Date | 10-31-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.34 | $1.05 |
| 52 Week High | $13.78 | $8.00 |
| Indicator | LITM | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 43.19 |
| Support Level | $3.10 | $1.57 |
| Resistance Level | $3.70 | $2.19 |
| Average True Range (ATR) | 0.34 | 0.22 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 73.26 | 26.02 |
Snow Lake Resources Ltd is a Canadian nuclear fuel cycle and critical minerals company with a portfolio of U.S.-focused uranium projects, including the Pine Ridge Uranium Project in the Powder River Basin in Wyoming. The company also holds exploration-stage critical minerals projects including the Snow Lake Lithium Project, Shatford Lake Lithium Project, and Engo Valley Uranium Project in Manitoba, Canada, and Namibia. Snow Lake has investments in companies with critical minerals assets, including rare earths and lithium in North America. The primary commercial use for U3O8 is as fuel for nuclear power plants to generate electricity.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.